Oct. 28, 2009 (Business Wire) -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) announced today that it will report its financial results for the quarter ended September 30, 2009, on Tuesday, November 3, 2009 at approximately 8:00 am Eastern Time (ET). The release will be followed by a live conference call, which will begin at approximately 10:00 am Eastern Time (ET) on Tuesday, November 3, 2009.
Participating in the call from Enzon’s executive management team will be Jeffrey H. Buchalter, President and Chief Executive Officer, and Craig Tooman, Executive Vice President, Finance and Chief Financial Officer.
All interested parties may access the call by using the following information:
| Domestic Dial-In Number: | | | | | (877) 397-0272 |
| International Dial-In Number: | | | | | (719) 325-4861 |
| Access Code: | | | | | Enzon |
The call will also be available via live audio webcast at the following site: http://investor.enzon.com/eventdetail.cfm?eventid=74303. Listeners should go to the website at least fifteen minutes before this event to download and install any necessary audio software. For those unable to attend the live audio webcast, a replay will be available beginning approximately one hour after the event. Additionally, a telephonic rebroadcast will also be available following the call. The rebroadcast will begin on Tuesday, November 3, 2009 at approximately 1:00 pm Eastern Time (ET) and end on Tuesday, November 10, 2009 at approximately (no time specified) Eastern Time (ET). It may be accessed using the following information:
| Domestic Dial-In Number: | | | | | (888) 203-1112 |
| International Dial-In Number: | | | | | (719) 457-0820 |
| Replay Passcode: | | | | | 6129874 |
About Enzon
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing, manufacturing and commercializing important medicines for patients with cancer and other life-threatening conditions. The Company has a portfolio of four marketed products, Oncaspar®, DepoCyt®, Abelcet® and Adagen®. Enzon’s drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform and the Locked Nucleic Acid (LNA) technology. Enzon’s PEGylation technology was used to develop two of its products, Oncaspar and Adagen, and has created a royalty revenue stream from licensing partnerships for other products developed using the technology. Enzon also engages in contract manufacturing for several pharmaceutical companies to broaden its revenue base. Further information about Enzon and this press release can be found on the Company’s web site at www.enzon.com.
